Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.
about
Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@en
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@nl
type
label
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@en
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@nl
prefLabel
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@en
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@nl
P2093
P2860
P356
P1476
Screening of JAK2 V617F and MP ...... JC17, ST13, TOP1MT, and NTRK1.
@en
P2093
Carla Al Assaf
Carlos Graux
Els Lierman
Johan Billiet
Timothy Devos
P2860
P304
P356
10.1111/BJH.12790
P407
P577
2014-02-26T00:00:00Z